

November 10, 2024

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
---	---

Dear Sir / Madam,

Sub: Corrigendum to the Statement of Unaudited Consolidated financial results of the Company for the quarter and half year ended 30 September 2024 - Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "SEBI Listing Regulations")

Ref: Our letter dated November 9, 2024 intimating the Outcome of Board Meeting.

This is to inform that the Board of Directors of the Company had in its meeting held on November 9, 2024, approved the Statement of Unaudited Consolidated Financial Results of the Company for the quarter and half-year ended on September 30, 2024 and the necessary disclosures were made under Regulation 30 of the SEBI Listing Regulations vide acknowledgement nos. NSE 2024/Nov/6907/6984 and BSE 8190588 dated November 9, 2024.

Subsequently, a typographical error was noticed in the Statement of Unaudited Consolidated Financial Results in point no. 12 under the heading of 'Out of total comprehensive income above, Profit for the year attributable to Owners of the Holding Company' for the unaudited half year ended September 30, 2023, which was erroneously mentioned as 9,299.9 instead of 13,279.3.

We confirm that there is no other change in the Statement of Unaudited Consolidated Financial Results for the quarter and half year ended September 30, 2024 and also confirm that the rectification of the aforesaid error does not have any impact on the consolidated financial results for the quarter and half year ended September 30, 2024, as reviewed by the Audit Committee and Approved by the Board of Directors of the Company or any other information disclosed. We regret the inconvenience caused, if any.

We now submit Statement of Unaudited Consolidated Financial Results for the quarter and half-year ended on September 30, 2024 correcting the aforesaid typographical error.

Please take the information on record.

Yours faithfully,
For **AUROBINDO PHARMA LIMITED**

B. Adi Reddy
Company Secretary

Enclosures: as above

AUROBINDO PHARMA LIMITED

(CIN : L24239TG1986PLC015190)

www.aurobindo.com

PAN No. AABCA7366H


Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithriviham, Ameerpet, Hyderabad - 500 038, Telangana., India. Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833
Email: info@aurobindo.com Website: www.aurobindo.com

(All amounts are in ₹ millions, unless otherwise stated)

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2024

	Particulars	Quarter ended			Half year ended		Year ended
		30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2024
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from operations						
	(a) Net sales/ income from operations	76,462.1	74,576.5	71,507.1	151,038.6	139,413.5	287,045.0
	(b) Other operating income	1,498.6	1,093.7	687.1	2,592.3	1,285.9	2,973.7
	Total revenue from operations	77,960.7	75,670.2	72,194.2	153,630.9	140,699.4	290,018.7
2	Other income						
	(a) Foreign exchange gain (net)	145.8	10.0	-	155.8	78.9	387.8
	(b) Others	1,214.2	2,199.3	1,869.8	3,413.5	2,656.3	5,186.0
	Total other income	1,360.0	2,209.3	1,869.8	3,569.3	2,735.2	5,573.8
	Total income (1+2)	79,320.7	77,879.5	74,064.0	157,200.2	143,434.6	295,592.5
3	Expenses						
	(a) Cost of materials consumed	27,418.5	24,666.6	27,089.1	52,085.1	54,657.4	107,761.4
	(b) Purchase of stock-in-trade	7,470.3	6,800.1	6,310.7	14,270.4	12,112.3	27,729.3
	(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(2,786.1)	(739.9)	(1,032.4)	(3,526.0)	(2,855.2)	(9,461.7)
	(d) Employee benefits expense	11,094.8	10,719.5	9,549.7	21,814.3	19,069.4	39,229.4
	(e) Finance costs	1,127.0	1,110.4	681.8	2,237.4	1,247.3	2,897.1
	(f) Foreign exchange loss (net)	-	-	297.9	-	-	-
	(g) Depreciation and amortisation expense	3,822.8	4,041.8	4,175.0	7,864.6	7,440.6	15,216.6
	(h) Other expenses	19,101.8	18,028.2	16,244.8	37,130.0	32,169.5	66,330.3
	Total expenses	67,249.1	64,626.7	63,316.6	131,875.8	123,841.3	249,702.4
4	Profit before share of profit of associates and joint ventures, exceptional items and tax (1+2-3)	12,071.6	13,252.8	10,747.4	25,324.4	19,593.3	45,890.1
5	Share of loss of associates and joint ventures, net of tax	3.0	(13.9)	9.0	(10.9)	(19.1)	(171.6)
6	Profit before exceptional items and tax (4+5)	12,074.6	13,238.9	10,756.4	25,313.5	19,574.2	45,718.5
7	Exceptional items (refer note 4)	-	-	-	-	697.5	1,918.6
8	Profit before tax (6-7)	12,074.6	13,238.9	10,756.4	25,313.5	18,876.7	43,799.9
9	Tax expense						
	Current tax	3,221.3	4,492.7	4,818.3	7,714.0	8,223.0	17,775.4
	Deferred tax	683.8	(436.0)	(1,581.3)	247.8	(2,562.8)	(5,665.2)
	Total tax expense	3,905.1	4,056.7	3,237.0	7,961.8	5,660.2	12,110.2
10	Profit for the period (8-9)	8,169.5	9,182.2	7,519.4	17,351.7	13,216.5	31,689.7
11	Other comprehensive Income						
	A) Items that will not be reclassified subsequently to profit or loss:						
	i) Re-measurement of defined employee benefit liability	(71.4)	(5.6)	(42.3)	(77.0)	(22.7)	(157.3)
	ii) Equity investments through other comprehensive income – net change in fair value	46.2	1.7	7.6	47.9	(20.2)	20.9
	iii) Income-tax relating to items that will not be reclassified to profit or loss	8.1	1.4	(5.9)	9.5	6.0	29.5
	B) Items that will be reclassified subsequently to profit or loss:						
	i) Exchange differences on translating the financial statements of foreign operations	2,719.9	(408.0)	554.6	2,311.9	247.2	1,098.5
	ii) Income-tax on items that will be reclassified subsequently to profit or loss	-	-	-	-	-	-
	Total other comprehensive income/(loss) for the period (net of tax)	2,702.8	(410.5)	514.0	2,292.3	210.3	991.6
12	Total comprehensive income for the period (net of tax) (10+11)	10,872.3	8,771.7	8,033.4	19,644.0	13,426.8	32,681.3
	Attributable to:						
	Owners of the Holding Company	10,876.6	8,781.7	8,085.8	19,658.3	13,489.6	32,721.3
	Non-controlling interest	(4.3)	(10.0)	(52.4)	(14.3)	(62.8)	(40.0)
	Out of total comprehensive income above, Profit for the period attributable to:						
	Owners of the Holding Company	8,173.8	9,192.2	7,571.8	17,366.0	13,279.3	31,729.7
	Non-controlling interest	(4.3)	(10.0)	(52.4)	(14.3)	(62.8)	(40.0)
	Other comprehensive income/(loss) attributable to:						
	Owners of the Holding Company	2,702.8	(410.5)	514.0	2,292.3	210.3	991.6
	Non-controlling interest	-	-	-	-	-	-
13	Paid-up equity share capital (face value ₹ 1 per share) (Refer note 7)	580.8	585.9	585.9	580.8	585.9	585.9
14	Other equity						297,842.1
15	Earnings per equity share (face value ₹ 1 per share)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)
	(a) Basic (in ₹)	14.00	15.69	12.83	29.69	22.57	54.16
	(b) Diluted (in ₹)	14.00	15.69	12.83	29.69	22.57	54.16



Sl. No.	Particulars	As at	As at
		30.09.2024	31.03.2024
		Unaudited	Audited
	ASSETS		
1	Non-current assets		
	Property, plant and equipment	111,256.0	112,608.3
	Capital work-in-progress	34,966.0	27,393.9
	Right-of-use assets	3,019.3	2,846.8
	Goodwill	6,299.9	5,951.5
	Other intangible assets	21,768.7	23,521.3
	Intangible assets under development	12,017.0	11,293.3
	Investments accounted for using the equity method	898.9	947.8
	Financial assets		
	Investments	2,064.7	2,268.7
	Loans	61.0	58.3
	Trade receivables	1,732.6	-
	Other financial assets	5,122.9	3,510.0
	Deferred tax assets (net)	12,033.1	12,126.4
	Non-current tax assets (net)	4,840.4	3,832.9
	Other non-current assets	2,607.6	2,299.6
	Total non-current assets	218,688.1	208,658.8
2	Current assets		
	Inventories	104,318.6	98,082.3
	Financial assets		
	Investments	285.2	505.8
	Trade receivables	53,882.8	48,167.4
	Cash and cash equivalents	39,039.7	33,934.8
	Bank balances other than cash and cash equivalents	29,357.4	28,848.2
	Loans	138.8	128.6
	Other financial assets	6,543.3	2,631.1
	Current tax assets (net)	-	56.7
	Other current assets	28,690.6	25,364.3
	Total current assets	262,256.4	237,719.2
3	Assets held for sale	-	4,337.1
	TOTAL ASSETS (1+2+3)	480,944.5	450,715.1
	EQUITY AND LIABILITIES		
1	Equity		
	Equity share capital (Refer note 7)	580.8	585.9
	Other equity	308,203.1	297,842.1
	Equity attributable to owners of the Parent Company	308,783.9	298,428.0
	Non-controlling interest	65.7	80.0
	Total equity	308,849.6	298,508.0
	Liabilities		
2	Non-current liabilities		
	Financial liabilities		
	Borrowings	19,479.9	21,349.0
	Lease liabilities	2,429.5	2,525.3
	Others	143.0	154.2
	Provisions	2,473.7	2,257.0
	Deferred tax liabilities (net)	3,706.9	3,565.6
	Other non-current liabilities	456.1	364.7
	Total non-current liabilities	28,689.1	30,215.8
3	Current liabilities		
	Financial liabilities		
	Borrowings	61,428.8	41,803.2
	Lease liabilities	934.3	798.8
	Trade payables		
	total outstanding dues of micro enterprises and small enterprises	832.5	791.5
	total outstanding dues of creditors other than micro enterprises and small enterprises	43,498.8	43,750.1
	Other financial liabilities	23,337.4	21,015.9
	Other current liabilities	6,691.9	8,773.8
	Provisions	3,045.8	2,567.9
	Current tax liabilities (net)	3,636.3	2,490.1
	Total current liabilities	143,405.8	121,991.3
	TOTAL EQUITY AND LIABILITIES (1+2+3)	480,944.5	450,715.1



Sl. No.	Particulars	For the half year ended 30.09.2024	For the half year ended 30.09.2023
		Unaudited	Unaudited
1	CASH FLOW FROM OPERATING ACTIVITIES		
	Net profit before tax	25,313.5	18,876.7
	Adjustments to reconcile profit before tax to net cash flows:		
	Depreciation and amortisation expense	7,864.6	7,440.6
	Allowance for credit losses on trade receivables and other advances (net)	188.1	207.0
	Liabilities no longer required written back (net)	(22.2)	(41.3)
	Mark-to-market (gain)/loss on derivative financial instruments	(34.3)	(35.5)
	Unrealised foreign exchange gain (net)	(1,002.5)	(1,006.1)
	Loss on sale / write-off of property, plant and equipment and intangibles under development (net)	35.2	91.1
	Share of loss of associate and joint ventures	10.9	19.1
	Profit on sale of current investment	(53.8)	-
	Finance costs	2,166.0	1,181.1
	Interest income	(1,521.3)	(1,327.7)
	Effect of exchange rate changes	1,324.9	306.4
	Operating profit before working capital changes	34,269.1	25,711.4
	Movements in working capital:		
	Increase in inventories	(6,236.3)	(7,711.1)
	Increase in trade receivables	(6,041.8)	(865.5)
	Increase in other financial assets	(5,369.1)	(1,318.3)
	Increase in other assets	(3,505.5)	(2,755.9)
	(Increase)/decrease in loans	(12.9)	-
	(Decrease)/increase in trade payables	(606.3)	6,162.9
	Increase in provision for retirement benefits and others	674.0	41.8
	Decrease in other liabilities	(2,180.8)	(646.5)
	Increase in other financial liabilities	3,066.0	2,801.8
	Cash generated from operating activities	14,056.4	21,420.6
	Direct taxes paid (net of refunds)	(7,532.2)	(6,417.8)
	Net cash generated from operating activities (A)	6,524.2	15,002.8
2	CASH FLOW FROM INVESTING ACTIVITIES		
	Purchase of property, plant and equipment, including movement in capital work-in-progress, capital advances and capital creditors (net)	(7,970.8)	(14,955.6)
	Purchase of intangible assets and intangible assets under development	(830.0)	(5,833.6)
	Proceeds from sale of property, plant and equipment and intangible assets	427.8	210.1
	Purchase of controlling interest in a subsidiary	(121.5)	-
	(Purchase)/proceeds of non-current investments	(103.0)	12.8
	(Purchase) /proceeds of non-current investments made in joint ventures	38.0	(146.3)
	Proceeds from sale of non-current investments	583.8	383.3
	Purchase of current investments	(2.4)	(12.9)
	Proceeds from sale of current investments	-	824.2
	Movement in bank balances not considered as cash and cash equivalents (net)	(510.0)	(12,448.9)
	Interest received	1,405.9	1,354.4
	Net cash used in investing activities (B)	(7,082.2)	(30,612.5)
3	CASH FLOW FROM FINANCING ACTIVITIES		
	Buy back of equity shares (including tax and transaction cost)	(9,302.4)	-
	Proceeds from non-current borrowings	2,782.6	11,202.6
	Repayment of non-current borrowings	(95.9)	(55.9)
	Proceeds of current borrowings (net)	14,695.5	2,694.2
	Finance costs paid	(2,069.2)	(1,109.0)
	Repayment of lease liabilities (net)	(551.8)	193.7
	Dividends paid on equity shares	(6.6)	0.7
	Net cash generated from financing activities (C)	5,452.2	12,926.3
	Net increase/(decrease) in cash and cash equivalents (A + B + C)	4,894.2	(2,683.4)
	Cash and cash equivalents at the beginning of the year	33,854.3	43,922.7
	Add: Cash and cash equivalents on acquisition of a subsidiary	6.6	-
	Effect of exchange differences on cash and cash equivalents	208.0	49.6
	Cash and cash equivalents at the end of the period	38,963.1	41,288.9
	Cash and cash equivalents comprise of:		
	Cash on hand	149.9	3.1
	Balance with banks		
	- on current account	18,725.7	13,412.4
	- on cash credit account (net)	720.4	708.7
	- on deposit account	19,367.1	27,164.7
	Cash and cash equivalents considered for cash flows	38,963.1	41,288.9



K-4



NOTES:

- 1 The above unaudited consolidated financial results of Aurobindo Pharma Limited ("the Company") including its subsidiaries (collectively known as "the Group") and its associates and joint ventures has been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 ("the Act"), read with the relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 2 The above unaudited consolidated financial results has been prepared in accordance with principles and procedures as set out in the Ind AS 110 on "Consolidated financial statements" and Ind AS 28 on "Investments in Associates and Joint ventures" notified under Section 133 of the Act and Companies (Indian Accounting Standards) Rules, 2015, as amended.
- 3 The above unaudited consolidated financial results of the Group as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on November 9, 2024. The results for the quarter and half year ended September 30, 2024 has been reviewed by the statutory auditors of the Company. The statutory auditors of the Company have issued an unmodified conclusion in respect of the limited review for the quarter and half year ended September 30, 2024.
- 4 Exceptional items represent the following items which have been credited/(debited) to consolidated statement of profit and loss.


Particulars	Quarter ended 30.09.2024	Quarter ended 30.06.2024	Quarter ended 30.09.2023	Half Year ended 30.09.2024	Half Year ended 30.09.2023	Year ended 31.03.2024
Loss on restructuring of business (refer note i)	-	-	-	-	(697.5)	(986.6)
Gain on settlement with customer (refer note ii)	-	-	-	-	-	1,306.0
Loss on write-off of non-current assets (refer note iii)	-	-	-	-	-	(2,238.0)
Total loss	-	-	-	-	(697.5)	(1,918.6)

Note:

- i) Accrual of severance pay and certain demolition charges on account of restructuring of business of Auro PR Inc., a step-down subsidiary of the Company.
- ii) Gain arising on account of settlement of balances with a customer by Auro PR Inc., a step-down subsidiary of the Company.
- iii) Loss arising on account of write-down of certain non-current assets held by Eugia US Manufacturing LLC, a step-down subsidiary of the Company, to its fair value less cost to sell, consequent to the sale of the assets.

- 5 The Group operates in only one reportable segment viz., 'Pharmaceuticals' in accordance with Ind AS 108, "Operating Segment".
- 6 During the quarter and half year ended September 30, 2024:
- The Group acquired 520 equity shares (representing 52% stake) in Purple Bellflower (Pty) Limited, South Africa through its wholly owned subsidiary Aurogen South Africa (Pty) Limited. Consequent to the said acquisition, Purple Bellflower (Pty) Limited has become a wholly owned subsidiary of Aurogen South Africa (Pty) Limited.
 - The Group acquired 500 equity shares (representing 100% stake) in Ace Laboratories Limited, UK through its wholly owned step-down subsidiary Agile Pharma BV.
 - Aurex B.V. The Netherlands, merged with Aurobindo Pharma B.V, The Netherlands w.e.f. April 1, 2024.
 - The Parent Company acquired 590,361 (representing 49% stake) in GLS Pharma Limited, India. Consequent to the said acquisition, GLS Pharma become wholly owned subsidiary of Aurobindo Pharma Limited w.e.f October 25, 2024.
- 7 The Board of Directors of parent company at their meeting held on July 18, 2024, approved buyback of 5,136,986 fully paid-up equity shares of face value of ₹ 1 each (representing 0.88% of the total number of equity share shares of the parent company) for an aggregate value not exceeding ₹ 7,500.0 million (buyback size) (excluding transaction cost and tax on buyback) at a maximum buyback price of ₹ 1,460/- per equity share. Upon completion of the buyback, the parent company extinguished the equity shares in compliance with applicable rules and regulations.
- Consequently, the paid up equity share capital has been reduced by ₹ 5.1 million. The aggregate amount paid for buyback is ₹ 9,302.4 million including tax and related expenses.

By Order of the Board
For Aurobindo Pharma Limited



K.Nithyananda Reddy
Vice Chairman & Managing Director
DIN-01284195

Place: Hyderabad
Date : November 9, 2024

